
|Videos|July 5, 2021
Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency
Author(s)Saro Arakelians, PharmD
Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.
Advertisement
Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:
- For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
- Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
- Chronic immune thrombocytopenia (ITP) in adults.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Halfway There Is Nowhere
2
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
3
CagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials
4
Metformin Cuts Long COVID Risk by 50%, New Trial Confirms
5


















































































































